DataVXSmallPaper
journal article·2020-11Open access

Severe Acute Respiratory Syndrome Coronavirus‐2 Spike Protein Nanogel as a Pro‐Antigen Strategy with Enhanced Protective Immune Responses

Long Chen, Bo Liu, Peng Sun, Wenjun Wang, Shiqiang Luo, Wenyuan Zhang, Yuanfan Yang, Zihao Wang, Jian Lin, Peng R. Chen

Small· Volume 16· Issue 46
Publisher pageOpen full text
Source abstract

Abstract

Abstract Prevention and intervention methods are urgently needed to curb the global pandemic of coronavirus disease‐19 caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). Herein, a general pro‐antigen strategy for subunit vaccine development based on the reversibly formulated receptor binding domain of SARS‐CoV‐2 spike protein (S‐RBD) is reported. Since the poor lymph node targeting and uptake of S‐RBD by antigen‐presenting cells prevent effective immune responses, S‐RBD protein is formulated into a reversible nanogel (S‐RBD‐NG), which serves as a pro‐antigen with enhanced lymph node targeting and dendritic cell and macrophage accumulation. Synchronized release of S‐RBD monomers from the internalized S‐RBD‐NG pro‐antigen triggers more potent immune responses in vivo. In addition, by optimizing the adjuvant used, the potency of S‐RBD‐NG is further improved, which may provide a generally applicable, safer, and more effective strategy for subunit vaccine development against SARS‐CoV‐2 as well as other viruses.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Immunotherapy and Immune Responses · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing National Laboratory for Molecular Sciences Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education College of Chemistry and Molecular Engineering Peking University Beijing 100871 China

Department of Microorganism Engineering Beijing Institute of Biotechnology Beijing 100071 China

Key Laboratory of Infection and Immunity Institute of Biophysics Chinese Academy of Sciences College of Life Sciences University of the Chinese Academy of Sciences Beijing 100101 China

Institute of Physical Science and Information Anhui University Hefei 230601 China

Beijing Institute of Pharmacology and Toxicology Beijing 100850 China

Peking‐Tsinghua Center for Life Sciences Peking University Beijing China

Funding

National Natural Science Foundation of China · National Basic Research Program of China

References (35)

Show source-provided references
1. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
2. Johns Hopkins Coronavirus Resource Center https://coronavirus.jhu.edu/map.html(accessed: June 2020).
3. 10.1038/s41422-020-0282-010.1038/s41422-020-0282-0 ↗
4. 10.1016/j.cell.2020.05.02510.1016/j.cell.2020.05.025 ↗
5. 10.1007/s40475-020-00201-610.1007/s40475-020-00201-6 ↗
6. 10.1126/science.abc193210.1126/science.abc1932 ↗
7. 10.1016/S0140-6736(20)31208-310.1016/S0140-6736(20)31208-3 ↗
8. 10.1016/j.bcp.2016.05.00110.1016/j.bcp.2016.05.001 ↗
9. 10.1016/j.xphs.2017.04.03710.1016/j.xphs.2017.04.037 ↗
10. 10.4161/hv.2746410.4161/hv.27464 ↗
11. 10.1586/erv.12.12610.1586/erv.12.126 ↗
12. 10.1016/j.virol.2009.07.01810.1016/j.virol.2009.07.018 ↗
13. 10.4049/jimmunol.174.8.490810.4049/jimmunol.174.8.4908 ↗
14. 10.1126/science.abc224110.1126/science.abc2241 ↗
15. 10.1016/j.cell.2020.06.03510.1016/j.cell.2020.06.035 ↗
16. 10.1126/science.113608010.1126/science.1136080 ↗
17. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
18. 10.1016/j.biomaterials.2018.03.03610.1016/j.biomaterials.2018.03.036 ↗
19. 10.1038/s41586-020-2180-510.1038/s41586-020-2180-5 ↗
20. 10.1038/s41594-020-0469-610.1038/s41594-020-0469-6 ↗
21. 10.1016/j.molmed.2011.11.00210.1016/j.molmed.2011.11.002 ↗
22. 10.1038/nri348810.1038/nri3488 ↗
23. 10.1038/nmat377510.1038/nmat3775 ↗
24. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
25. 10.3390/vaccines501000610.3390/vaccines5010006 ↗
26. 10.3389/fimmu.2018.0023010.3389/fimmu.2018.00230 ↗
27. 10.1016/j.vaccine.2014.12.04510.1016/j.vaccine.2014.12.045 ↗
28. 10.1172/JCI7991510.1172/JCI79915 ↗
29. Hanson M. C. · Methods Mol. Biol. · 2017 · 1494 · 14510.1007/978-1-4939-6445-1_10 ↗
30. 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
31. 10.1172/JCI9764210.1172/JCI97642 ↗
32. 10.4049/jimmunol.110176410.4049/jimmunol.1101764 ↗
33. 10.1016/j.micpath.2019.02.03010.1016/j.micpath.2019.02.030 ↗
34. 10.1021/acscentsci.9b0117410.1021/acscentsci.9b01174 ↗
35. 10.1111/imr.1236710.1111/imr.12367 ↗